Pharmacology · Cardiovascular

Calcium Channel Blockers & Diuretics

Mechanisms, subclass distinctions, metabolic effects, and combination strategies

Calcium channel blockers divide into two pharmacologically distinct classes based on tissue selectivity: dihydropyridines act almost exclusively on vascular smooth muscle, lowering resistance without cardiac effects, while non-dihydropyridines act equally on vascular and cardiac tissue, adding negative chronotropy, negative dromotropy, and negative inotropy that make them useful for rate control but dangerous in heart failure with reduced ejection fraction and contraindicated with beta-blockers.
Among dihydropyridines, amlodipine is the first choice for most patients — particularly those with heart failure with reduced ejection fraction where its safety is well-established — while long-acting nifedipine and felodipine are alternatives; short-acting nifedipine is avoided due to reflex tachycardia and adverse outcome data.
The three diuretic subclasses act at consecutive nephron segments: thiazides and thiazide-like agents at the distal convoluted tubule (chlorthalidone preferred for its longer half-life and stronger outcome evidence), loop diuretics at the thick ascending limb (needed when estimated glomerular filtration rate falls below 30), and potassium-sparing agents including mineralocorticoid receptor antagonists at the collecting duct (spironolactone is the best fourth-line agent for resistant hypertension by PATHWAY-2 evidence).
Thiazides carry a predictable metabolic burden — hypokalemia in 10 to 30 percent of patients (correct magnesium first), hyperuricemia (use losartan as the RAAS partner when gout coexists), dose-dependent new-onset diabetes (most prominent above hydrochlorothiazide 25 mg, least with indapamide), and hyponatremia (most common in elderly women, higher risk with chlorthalidone than hydrochlorothiazide) — effects that inform combination partner selection.
The ACCOMPLISH trial established that a calcium channel blocker plus a RAAS inhibitor reduces cardiovascular events by 20 percent relative to a RAAS inhibitor plus hydrochlorothiazide, making this the preferred two-drug combination; non-dihydropyridine calcium channel blockers combined with beta-blockers remain absolutely contraindicated due to the risk of complete heart block.

Abbreviations: CCB = calcium channel blocker · DHP = dihydropyridine · Non-DHP = non-dihydropyridine · AV = atrioventricular · SA = sinoatrial · HFrEF = heart failure with reduced ejection fraction · NCC = sodium-chloride cotransporter · NKCC2 = sodium-potassium-2-chloride cotransporter · MR = mineralocorticoid receptor · ENaC = epithelial sodium channel · MRA = mineralocorticoid receptor antagonist · CKD = chronic kidney disease · eGFR = estimated glomerular filtration rate · HTN = hypertension · HCTZ = hydrochlorothiazide · RAAS = renin-angiotensin-aldosterone system · ADH = antidiuretic hormone · TPR = total peripheral resistance · RRR = relative risk reduction · ACEi = angiotensin converting enzyme inhibitor · ARB = angiotensin receptor blocker · AKI = acute kidney injury

Calcium Channel Blockers — DHP vs Non-DHP

Tissue Selectivity Is the Key Distinction

Dihydropyridine vs Non-Dihydropyridine Comparison

Feature	Dihydropyridine (DHP)	Non-Dihydropyridine (Non-DHP)
Tissue selectivity	Vascular smooth muscle (high selectivity)	Vascular + cardiac tissue (equal effect)
Heart rate	May increase (reflex tachycardia)	Decreases (negative chronotropy)
AV conduction	No significant effect	Slows (negative dromotropy)
Contractility	Minimal effect	Decreases (negative inotropy)
Main adverse effects	Peripheral edema, flushing, headache	Bradycardia, AV block, constipation (verapamil)
HFrEF	Safe — amlodipine preferred	Contraindicated
Atrial fibrillation rate control	Not used	Yes — diltiazem or verapamil
With beta-blockers	Acceptable	Contraindicated — risk of complete heart block
Prototype agents	Amlodipine, nifedipine (long-acting only), felodipine	Verapamil, diltiazem

Diuretic Subclasses — Site of Action & Clinical Role

Three Subclasses, Three Nephron Segments

Diuretic Quick Reference

Subclass	Site / Transporter	Preferred Agent	Primary Role	Calcium Effect
Thiazide / thiazide-like	Distal convoluted tubule — NCC (sodium-chloride cotransporter)	Chlorthalidone (longest half-life, best evidence)	First-line antihypertensive; isolated systolic hypertension in elderly	Increases reabsorption (useful in nephrolithiasis)
Loop	Thick ascending limb — NKCC2 (sodium-potassium-2-chloride cotransporter)	Furosemide, torsemide	Advanced CKD (eGFR below 30); heart failure volume overload; most potent	Increases excretion
Potassium-sparing / MRA	Collecting duct — MR (mineralocorticoid receptor) or ENaC (epithelial sodium channel)	Spironolactone (PATHWAY-2 best 4th-line for resistant HTN); eplerenone (selective, fewer hormonal effects)	Resistant hypertension; primary aldosteronism; HFrEF (guideline-directed)	No significant effect

Thiazide Metabolic Adverse Effects

Most Common

Hypokalemia

10–30% of patients
Increased Na delivery to collecting duct → aldosterone-mediated K secretion
Risk of arrhythmias with digoxin or cardiac disease
Correct Mg first — Mg depletion impairs K conservation

Metabolic

Hyperuricemia

Reduced uric acid excretion (tubular competition) + volume contraction
Asymptomatic hyperuricemia alone: not a contraindication
With gout: use losartan as RAAS partner (uricosuric effect)

Glucose

New-Onset Diabetes

Dose-dependent; most prominent above HCTZ 25 mg/day
Mechanism: hypokalemia impairs insulin secretion
Chlorthalidone 12.5 mg: modest effect
Indapamide: most favorable metabolic profile

Electrolyte

Hyponatremia

Most common in elderly women
Volume depletion stimulates ADH → free water retention
Chlorthalidone carries higher risk than HCTZ (longer half-life)
Monitor closely in first weeks of therapy

Combination Strategies

Preferred Combinations

Evidence-Based Pairings

CCB + RAAS inhibitor: ACCOMPLISH trial — 20% RRR vs RAAS + HCTZ; synergistic (CCB reduces TPR; RAAS inhibitor blunts reactive RAAS and reduces edema)
RAAS inhibitor + thiazide: diuretic activates RAAS, amplifying RAAS inhibitor effect; RAAS inhibitor blunts hypokalemia
Triple therapy (CCB + RAAS inhibitor + thiazide): standard of care for hypertension uncontrolled on dual therapy

Combinations to Avoid

Non-DHP CCB + beta-blocker: both suppress SA and AV nodes → complete heart block risk — contraindicated

ACEi + ARB (dual RAAS blockade): ONTARGET — no benefit, more AKI and hyperkalemia

Thiazide + loop diuretic: excessive natriuresis and volume depletion — specialist use only

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Whelton PK, Carey RM, Aronow WS, et al.	2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults	J Am Coll Cardiol. 2018;71(19):e127–e248
Mancia G, Kreutz R, Brunstrom M, et al.	2023 ESH guidelines for the management of arterial hypertension	J Hypertens. 2023;41(12):1874–2071
Opie LH, Schall R	Old antihypertensives and new diabetes	J Hypertens. 2004;22(8):1453–1458
ALLHAT Officers and Coordinators	Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (ALLHAT)	JAMA. 2002;288(23):2981–2997
Jamerson K, Weber MA, Bakris GL, et al.	Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients (ACCOMPLISH)	N Engl J Med. 2008;359(23):2417–2428
Nissen SE, Tuzcu EM, Libby P, et al.	Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure (CAMELOT)	JAMA. 2004;292(18):2217–2225
Staessen JA, Fagard R, Thijs L, et al.	Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension (Syst-Eur)	Lancet. 1997;350(9080):757–764
Ernst ME, Moser M	Use of diuretics in patients with hypertension	N Engl J Med. 2009;361(22):2153–2164
SHEP Cooperative Research Group	Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension (SHEP)	JAMA. 1991;265(24):3255–3264
PROGRESS Collaborative Group	Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack (PROGRESS)	Lancet. 2001;358(9287):1033–1041
Beckett NS, Peters R, Fletcher AE, et al.	Treatment of hypertension in patients 80 years of age or older (HYVET)	N Engl J Med. 2008;358(18):1887–1898
Williams B, MacDonald TM, Morant S, et al.	Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2)	Lancet. 2015;386(10008):2059–2068
Zannad F, McMurray JJ, Krum H, et al.	Eplerenone in patients with systolic heart failure and mild symptoms (EMPHASIS-HF)	N Engl J Med. 2011;364(1):11–21
Bakris GL, Agarwal R, Anker SD, et al.	Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD)	N Engl J Med. 2020;383(23):2219–2229
Carey RM, Calhoun DA, Bakris GL, et al.	Resistant hypertension: detection, evaluation, and management — a scientific statement from the American Heart Association	Hypertension. 2018;72(5):e53–e90